Moreover, we exploited a CIBERSORTx digital flow cytometric analysis of NSCLC RNA-Seq bulk tumors, and we identified that immune (CD45+), epithelial/cancer (EpCAM), and stromal (CD10+ and CD34+) subsets were expressed in NSCLC and associated with poor prognoses. The gene discussed is CD34; the disease is cancer.